Immix Biopharma Inc

자세한 내용은 Immix Biopharma Inc 회사

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

회사 정보

종목 코드 IMMX

회사 이름Immix Biopharma Inc

상장일Dec 16, 2021

CEODr. Ilya Rachman, M.D., Ph.D.

직원 수18

유형Ordinary Share

회계 연도 종료Dec 16

주소11400 West Olympic Blvd.

도시LOS ANGELES

증권 거래소NASDAQ Capital Market Consolidated

국가United States of America

우편 번호90064

전화18889581084

웹사이트https://immixbio.com/

종목 코드 IMMX

상장일Dec 16, 2021

CEODr. Ilya Rachman, M.D., Ph.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Jason Hsu, Ph.D.

Independent Director

4.86M

--

Ms. Helen C. Adams, CPA

Lead Independent Director

174.75K

-0.13%

Dr. Magda Marquet, Ph.D.

Independent Director

173.19K

+161.79%

Mr. Gabriel Morris

Chief Financial Officer, Director

--

Dr. Graham Ross

Acting Chief Medical Officer, Head - Clinical Development

--

Ms. Jane M. Buchan, Ph.D.

Independent Director

--

Dr. Ilya Rachman, M.D., Ph.D.

Chairman of the Board, Chief Executive Officer

--

Mr. Carey Ng, Ph.D.

Independent Director

--

Dr. Vladimir Torchilin, Ph.D.

Scientific Co-Founder

--

Ms. Yekaterina (Katie) Chudnovsky, J.D.

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Jason Hsu, Ph.D.

Independent Director

4.86M

--

Ms. Helen C. Adams, CPA

Lead Independent Director

174.75K

-0.13%

Dr. Magda Marquet, Ph.D.

Independent Director

173.19K

+161.79%

Mr. Gabriel Morris

Chief Financial Officer, Director

--

Dr. Graham Ross

Acting Chief Medical Officer, Head - Clinical Development

--

Ms. Jane M. Buchan, Ph.D.

Independent Director

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Thu, May 15

주주

주주 유형

주주

비율

Hsu (Jason)

17.45%

GKCC, LLC

11.64%

Rachman (Ilya M)

4.09%

Ng (Carey)

3.75%

Bleichroeder LP

3.05%

Other

60.03%

주주

비율

Hsu (Jason)

17.45%

GKCC, LLC

11.64%

Rachman (Ilya M)

4.09%

Ng (Carey)

3.75%

Bleichroeder LP

3.05%

Other

60.03%

주주 유형

주주

비율

Individual Investor

28.71%

Corporation

11.64%

Investment Advisor/Hedge Fund

7.98%

Investment Advisor

4.27%

Research Firm

0.06%

Venture Capital

0.05%

Other

47.29%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

65

14.67M

52.67%

-1.12M

2025Q1

66

14.50M

53.34%

-1.02M

2024Q4

67

14.42M

52.43%

-1.29M

2024Q3

66

15.60M

56.77%

-243.92K

2024Q2

66

15.89M

59.32%

-308.72K

2024Q1

64

15.43M

77.52%

+5.90M

2023Q4

57

11.10M

62.12%

+3.00M

2023Q3

52

12.47M

73.23%

+2.63M

2023Q2

46

9.35M

66.71%

-203.85K

2023Q1

40

9.11M

65.58%

-364.69K

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Hsu (Jason)

4.86M

17.45%

--

Apr 22, 2025

GKCC, LLC

3.24M

11.64%

--

Apr 22, 2025

Rachman (Ilya M)

1.14M

4.09%

+2.18K

+0.19%

Jun 18, 2025

Ng (Carey)

1.05M

3.75%

--

Apr 22, 2025

Bleichroeder LP

850.00K

3.05%

--

Mar 31, 2025

Cable Car Capital LLC

779.36K

2.8%

-16.74K

-2.10%

Mar 31, 2025

The Vanguard Group, Inc.

698.54K

2.51%

--

Mar 31, 2025

Morris (Gabriel S)

583.04K

2.09%

+2.23K

+0.38%

Jun 18, 2025

Lynwood Capital Management Inc.

405.00K

1.45%

+405.00K

--

Mar 31, 2024

Adams (Helen C)

174.75K

0.63%

-227.00

-0.13%

Apr 22, 2025

2.540USD

Immix Biopharma Inc

2.540

개요

회사

금융